NEU

0.81%

$12.25 neuren pharmaceuticals limited

The Whens and Whys of Top Biotech M&A Deals, page-47

First 47 Last

Share
Profile

Follow
Tangentland

5,852 Posts.

340

22/08/24

15:50

Post #: 75328344
Share

Originally posted by turbo: ↑

Jon is, rightfully so, placing an emphasis on moving into P3 for PMS and PH and the associated value uplift - it is his and the board's fiduciary duty to do so as they cannot assume a t/o will happen.

As others above have discussed, I believe this is the simple reason for the recent SP weakness. What we have is a group of institutional and other investors who do not have the performance time horizon for P3 trials so are reducing their exposure. Many other theories for the recent weakness have been thrown around, but what I have learnt over the years is that, despite the facade of sophistication, Occam's Razor usually operates in investment markets.

Now, many of these investors may be assuming a time horizon of 3+ years for P3 trials and that a t/o will not happen until then. However, I believe Jon still has the possibility of corporate action firmly in his mind post the meeting with the FDA next month. He has stressed the importance of this meeting beyond its prima facie purpose several times - and did so again yesterday at the biotech showcase in Melbourne - and some of his language has been interesting.

For example, during the Angelman webinar in response to a question around the future strategy for 2591 - time stamp 24:00 "the FDA meeting is very important. Until we know exactly what the P3 trial will look like we and others are not going to be able to make firm decisions around that."

Similarly, in response to a question about discussions with pharma - time stamp 46:50 "had a number of discussions and will continue to have discussions but we need to get through that meeting in September before we'll say anything more concrete than that".

Essentially, any acquirer is going to want to know what they are buying and how to value it - and that means understanding the dimensions of the P3 trials.

Then there is the pre-clinical work on the undisclosed indications. I have posted before I believe the purpose of this is squarely to maximise the value of the 2591 asset. Neuren will have their hands full running 2 P3 trials, I just can't see them initiating additional P2 trials at the same time.

So, I believe this company is still being set up for acquisition possibly before or during P3 but with a firm and achievable plan should this not occur.

Expand

Very well articulated Turbo.
They are covering a TO and a go it alone scenario for the best shareholder outcome. Depending on circumstances that may arise. Or may have aready arisen………..

.

NEU Price at posting: $15.20 Sentiment: Buy Disclosure: Held
11 Upvote

Reply

Top Stories

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Making money: How many microcaps should be in an investor's portfolio?

What each US election outcome would mean for Australian companies & investors

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

First 47 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $12.25		Change -0.100(0.81%)		Mkt cap ! $1.565B

Open	High	Low	Value	Volume
$12.20	$12.25	$12.02	$3.677M	302.0K

Buyers (Bids)

No.	Vol.	Price($)
1	1579	$12.21

Sellers (Offers)

Price($)	Vol.	No.
$12.26	1199	1

View Market Depth

No.	Vol.	Price($)
1	900	12.150
2	600	12.020
2	1083	12.010
19	11621	12.000
1	5000	11.980

Price($)	Vol.	No.
12.350	500	1
12.450	1000	1
12.490	678	1
12.500	2284	3
12.700	2000	1

Last trade - 16.10pm 01/11/2024 (20 minute delay)

NEU (ASX) Chart

The Whens and Whys of Top Biotech M&A Deals, page-47

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Making money: How many microcaps should be in an investor's portfolio?

What each US election outcome would mean for Australian companies & investors

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The Whens and Whys of Top Biotech M&A Deals, page-47

Top Stories

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Making money: How many microcaps should be in an investor's portfolio?

What each US election outcome would mean for Australian companies & investors

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News